IPO - Profile

Summary

We are a clinical stage biotherapeutics company advancing technologies to enable the development of orally administered biologics, which we believe have the potential to transform medicine and improve patient outcomes. We have developed the RaniPill capsule, which is our novel, proprietary and patented platform technology, intended to replace subcutaneous or IV injection of biologics with oral dosing. The RaniPill capsule is an orally ingestible pill approximately the size of a “000” capsule (or similar to the size of a standard fish oil or calcium pill) that is designed to automatically More

Offer Price Offer Size 3-Year Outlook Volatility First Day Turnover
$11.00 6,670,000 Positive High 14.56%

Offering Team

  • Legal counsel
  • Goodwin Procter LLP
  • Auditors
  • Ernst & Young LLP

Deal Highlights

Deal Tracker

IPO Dates

Filing 29 Jul, 2021

Offer 30 Jul, 2021

Look Ahead

Lock Up Expiry Jan 30, 2022

IPO Terms

Offer Price $11.00
Offer Size 6M

Market Sentiments

Stock Price